Infection Risk Associated with Daratumumab

BACKGROUND: Daratumumab is an IgG kappa monoclonal antibody (mAB) against CD38 which is expressed on myeloma cells. It has recently been approved for treatment of patients with relapsed refractory multiple myeloma. Our objective was to identify the potential infectious complications associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnsrud, Joyce J, Susanibar, Sandra, Jo-Kamimoto, Jorge, Johnsrud, Andrew J, Kothari, Atul, Burgess, Mary J, Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Maurizio, Davies, Faith, Morgan, Gareth, Vanrhee, Frits, Crescencio, Juan Carlos Rico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630755/
http://dx.doi.org/10.1093/ofid/ofx163.1884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630755/
http://dx.doi.org/10.1093/ofid/ofx163.1884

Ejemplares similares